Bicara Therapeutics Inc. Common Stock (BCAX)

FairStock Score: 26/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a value investor, I look for durable earnings and a margin of safety. Bicara does not yet have them. It is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors, with lead program ficerafusp alfa. Filed results show no revenue. The company lost $52.0 million in fiscal year 2023, $68.0 million in fiscal year 2024, and $137.9 million in fiscal year 2025. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $56.2 million; in fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $55.4 million. Trailing free cash flow was negative $135.2 million, a FairStock-calculated FCF yield of -11.8%. The balance sheet shows no debt by D/E of 0.00 and a FairStock-calculated Altman Z-Score of 15.63, but the Piotroski F-Score is 2/9, and the FairStock Score is 26/100. At the 2026-10-13 close of $17.34, market cap was $1.1 billion; FairStock-calculated P/E was -5.65 and P/B was 2.44, and the Lynch category is none because of losses in each of the last three years. Any moat is speculative: intellectual property and clinical data may matter, but there is no commercial product or revenue to prove pricing power. Growth today means growing losses, not sales. Graham would ask for demonstrated earnings and a margin of safety; Buffett would ask for an understandable, durable business. Bicara is an option on science, not a proven compounding machine. I would want far more clinical certainty and a better price before calling it a value opportunity.

In plain English: Bicara Therapeutics is a young drug company trying to develop treatments for solid tumors. It has no product sales yet and has been losing money, with heavy spending. At the 2026-10-13 close of $17.34, the price looks expensive compared with today's numbers because there are no profits to support it; the value mainly rests on whether its experimental treatment works.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer